scholarly journals Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis

1999 ◽  
Vol 81 (8) ◽  
pp. 1385-1391 ◽  
Author(s):  
A Scorilas ◽  
T Trangas ◽  
J Yotis ◽  
C Pateras ◽  
M Talieri
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Cancer Patients ◽  
Cathepsin D ◽  
Prognostic Value ◽  
Clinicopathological Characteristics ◽  
Breast Cancer Patients

Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients

1997 ◽  
Vol 116 (2) ◽  
pp. 177-183 ◽  
Author(s):  
P.M Ravdin ◽  
C.A de Moor ◽  
S.G Hilsenbeck ◽  
M.K Samoszuk ◽  
P.M Vendely ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cathepsin D ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Short Term

scholarly journals The Prognostic Value of Intermedin in Patients with Breast Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Yi-Min Lu ◽  
Jian-Bo Zhong ◽  
Hai-Yong Wang ◽  
Xiong-Fei Yu ◽  
Zhong-Qi Li
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Adverse Event ◽  
Multivariate Analysis ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Disease Free

This study aimed to evaluate the prognostic value of preoperative plasma intermedin levels in breast cancer patients. Plasma intermedin levels of 252 breast cancer women and 100 healthy women were determined using radioimmunoassay kit. Adverse event was defined as first local recurrence, distant metastasis, second primary cancer of another organ, or death from any cause during 5-year follow-up. Disease-free survival was defined as the time between surgery and the date of any adverse event whichever appeared first. Overall survival was defined from surgery to death for any cause. The relationships between plasma intermedin levels and clinical outcomes of breast cancer patients were evaluated using multivariate analysis. The results showed that preoperative plasma intermedin levels were substantially higher in patients than in healthy subjects usingt-test. Intermedin was identified as an independent predictor for 5-year mortality, adverse event, disease-free survival, and overall survival using multivariate analysis. Based on receiver operating characteristic curve analysis, preoperative plasma intermedin levels had high predictive value for 5-year mortality and adverse event. In conclusion, preoperative plasma intermedin levels are highly associated with poor patient outcomes and intermedin may be a potential prognostic biomarker for patients with breast cancer.

scholarly journals Determination of O6-Methylguanine in Dried Blood Spot of Breast Cancer Patients After Cyclophosphamide Administration

Heliyon ◽  
2021 ◽  
pp. e07558
Author(s):  
Yahdiana Harahap ◽  
Athalia Theda Tanujaya ◽  
Farhan Nurahman ◽  
Aurelia Maria Vianney ◽  
Denni Joko Purwanto
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Dried Blood Spot ◽  
Breast Cancer Patients ◽  
Cyclophosphamide Administration ◽  
Blood Spot

scholarly journals RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients

2006 ◽  
Vol 17 (3) ◽  
pp. 424-428 ◽  
Author(s):  
L. Mercatali ◽  
V. Valenti ◽  
D. Calistri ◽  
S. Calpona ◽  
G. Rosti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Cancer Patients ◽  
Rt Pcr ◽  
Healthy Donors

5012 ORAL Prognostic Value of TWIST1 Expression in Breast Cancer Patients

2011 ◽  
Vol 47 ◽  
pp. S333
Author(s):  
M. Riaz ◽  
A. Sieuwerts ◽  
M. Look ◽  
M. Smid ◽  
J. Foekens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Twist1 Expression

scholarly journals Comparing the Prognostic Value of PTEN and Akt Expression with the Mitotic Activity Index in Adjuvant Chemotherapy-Treated Node-Negative Breast Cancer patients aged <55 years

2007 ◽  
Vol 29 (1) ◽  
pp. 25-35
Author(s):  
Emiel A. M. Janssen ◽  
Håvard Søiland ◽  
Ivar Skaland ◽  
Einar Gudlaugson ◽  
Kjell H. Kjellevold ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cancer Patients ◽  
Mitotic Activity ◽  
Invasive Breast Cancer ◽  
Prognostic Value ◽  
Activity Index ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Mitotic Activity Index

Background: The prognostic value of the PI3K/Akt/mTOR pathway and PTEN in invasive breast cancer (IBC) is controversial. Cell proliferation, especially the Mitotic Activity Index (MAI), is strongly prognostic in lymph node-negative (LNneg) invasive breast cancer. However, its prognostic value has not been compared with the value of Akt and PTEN expression. Material and Methods: Prognostic comparison of Her2Neu, p110alpha (PIK3CA), Akt, mTOR, PTEN, MAI and cell-cycle regulators in 125 LNneg patients aged <55 years with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-based adjuvant systemic chemotherapy. Results: Twenty-one (17%) patients developed distant metastases = DMs (median follow-up: 134 months). p110alpha correlated (p = 0.01) with pAkt but only in PTEN-negatives; pAkt correlated (p = 0.02) with mTOR. PTEN-negativity correlated with high MAI, high grade and ER-negativity (p = 0.009). The MAI was the strongest prognosticator (Hazard Ratio = HR = 2.9, p = 0.01). Her2Neu/p110α/Akt/mTOR features have no additional prognostic value to the MAI. PTEN had additional value but only in MAI < 3 (39/125 = 31%; 8% DMs). 19/39 = 49% of the MAI < 3 patients have combined MAI < 3 / PTEN+ with 0% DMs, contrasting 15% DMs in MAI < 3 / PTEN− (p = 0.03). Conclusions: In T1−3N0M0 adjuvant CMF-treated breast cancer patients aged <55 years, MAI was the strongest survival predictor. The PI3K/Akt/mTOR pathway and cell-cycle regulator characteristics had no additional prognostic value, but PTEN has. Patients with combined MAI < 3 & PTEN-positivity had 100% survival. The small subgroup of MAI < 3 patients that died were PTEN-negative.

scholarly journals Prognostic and Clinicopathological Value of Cyclin E Expression in Breast Cancer: A Meta-Analysis

2021 ◽  
Author(s):  
Yufei Wang ◽  
Qijuan Yang ◽  
Deshou Ma ◽  
Zhijun Ma ◽  
Xiaowu Wang
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Meta Analysis ◽  
Cyclin E ◽  
Cochrane Collaboration ◽  
Clinicopathological Characteristics ◽  
Positive Lymph Node ◽  
Cancer Prognosis ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival

Abstract Background: Multiple studies have analyzed the correlation between Cyclin E and breast cancer prognosis, but the results are controversial. In this study, a meta-analysis was used to summarize the published reports, clarify the predictive value of Cyclin E in breast cancer, and the relationship with clinicopathological characteristics.Methods: A systematic search was retrieved in PubMed, Embase, Web of Science, Cochrane Collaboration Library on the comprehensive search strategy up to 24 August 2020. recurrence-free survival (RFS), overall survival (OS), and breast cancer-specific survival (BCSS) was estimated using pooled hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (95% CIs) by univariate and multivariate analysis.Results: Twenty-eight eligible studies met our inclusion criteria. The present meta-analysis indicates that high cyclin E expression is independently associated with poor OS, BCSS, and RFS in female breast cancer patients by univariate and multivariate analysis. Furthermore, higher histological grades, estrogen receptor (ER)-negativity, positive lymph node metastasis, younger patients, and premenopausal status were associated with Cyclin E overexpression. Conclusions: High expression of Cyclin E is associated with poor breast cancer outcomes and relevant to multiple clinical characteristics.

Sign in / Sign up

Export Citation Format

Share Document